Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates

August 27, 2026 - 11:07

Shanghai, August 26, 2026 - Shanghai Junshi Biosciences, a biopharmaceutical company focused on creating new treatments, has shared its financial results for the first half of 2026. The company reported total revenue of about 1.696 billion RMB for the six months ending June 30, marking a 45 percent jump compared to the same period last year.

The growth points to stronger sales of its core products and continued progress in its pipeline. Junshi Biosciences, which is listed on both the Hong Kong and Shanghai stock exchanges, said the results reflect its ongoing push to bring novel therapies to market.

Beyond the numbers, the company provided updates on its corporate activities. Management highlighted advances in its research programs and steps to expand its commercial reach. The company remains focused on areas with high unmet medical needs, particularly in oncology and other serious diseases.

Executives noted that the strong financial performance gives them room to invest further in drug development and to explore new partnerships. They also reaffirmed their commitment to improving patient access to their medicines.

The interim report covers the period ending June 30, 2026. Junshi Biosciences said it will continue to prioritize innovation and operational efficiency as it moves through the second half of the year.